Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
The DOI matches its Crossref record.
Abstract
We studied the effect of isoniazid administration on the cytochrome P4502E1-catalyzed elimination of chlorzoxazone and acetaminophen. Isoniazid, 300 mg daily, was administered for 7 days to a group of 10 volunteer slow acetylators. Acetaminophen, 500 mg, and chlorzoxazone, 750 mg, were administered on separate occasions before isoniazid, during the period of isoniazid administration, and after the discontinuation of isoniazid. Isoniazid inhibited the clearance of chlorzoxazone by 58%, as assessed from plasma data, and inhibited the formation of acetaminophen thioether metabolites (a measure of the formation of the hepatotoxin N-acetyl-p-benzoquinone imine and catechol oxidative metabolites of acetaminophen, as determined from their recovery in urine, by 63% and 49%, respectively. Two days after the discontinuation of isoniazid, the clearance of chlorzoxazone was increased over the value before isoniazid by 56%. Acetaminophen thioether but not catechol metabolites were increased by 56% 1 day after the discontinuation of isoniazid and had returned to the pre-isoniazid value 3 days after the discontinuation of isoniazid. We conclude that the time course of the interaction with regard to chlorzoxazone elimination and formation is compatible with an inhibition-induction effect of isoniazid on cytochrome P4502E1. The mechanism of this biphasic effect is probably induction by protein stabilization, which results in inhibition of catalytic activity while isoniazid is present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Bessems, J. G. M., & Vermeulen, N. P. E. (2001) · Critical Reviews in Toxicology · doi:10.1080/20014091111677 · Cited by 715
McGill, M. R., & Jaeschke, H. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1007-6 · Cited by 704
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses
Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., FitzGerald, G. A., Altman, R. B., & Klein, T. E. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000150 · Cited by 379
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation
MANYIKE, P., KHARASCH, E., KALHORN, T., & SLATTERY, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104736 · Cited by 355
Self-citationCYP induction-mediated drug interactions: in vitro assessment and clinical implications
Lin, J. H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0277-7 · Cited by 264
Chen, W., Koenigs, L. L., Thompson, S. J., Peter, R. M., Rettie, A. E., Trager, W. F., & Nelson, S. D. (1998) · Chemical Research in Toxicology · doi:10.1021/tx9701687 · Cited by 226
Self-citationCho, H.-J., Koh, W.-J., Ryu, Y.-J., Ki, C.-S., Nam, M.-H., Kim, J.-W., & Lee, S.-Y. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.05.012 · Cited by 173
Parkinson, A. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400107 · Cited by 169
“itors as well as inducers of CYP2E ( (37).”
BackgroundAssessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics
Girre, C., Lucas, D., Hispard, E., Menez, C., Dally, S., & Menez, J.-F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90524-x · Cited by 162
Can paracetamol (acetaminophen) be administered to patients with liver impairment?
Hayward, K. L., Powell, E. E., Irvine, K. M., & Martin, J. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12802 · Cited by 104
Valencia-Olvera, A. C., Morán, J., Camacho-Carranza, R., Prospéro-García, O., & Espinosa-Aguirre, J. J. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.05.014 · Cited by 36
Metadata
- Authors
- Zand, R., Nelson, S. D., Slattery, J. T., Thummel, K. E., Kalhorn, T. F., Adams, S. P., & Wright, J. M.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1993-08
- Volume
- 54
- Issue
- 2
- Pages
- 142-149
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2049849453
- Cited by
- 153
- References
- 0
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.